ZHEJIANG CONBA PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.48 CNY | +5.79% |
|
+8.09% | +8.51% |
Valuation
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 15,806 | 12,156 | 12,979 | 13,943 | - | - |
| Enterprise Value (EV) 1 | 15,806 | 12,156 | 12,979 | 13,943 | 13,943 | 13,943 |
| P/E ratio | -47.3 x | 33.8 x | 22 x | 17.9 x | 15.1 x | 13.4 x |
| Yield | - | - | 3.96% | 2.55% | 2.83% | - |
| Capitalization / Revenue | - | - | 1.93 x | 1.8 x | 1.55 x | 1.41 x |
| EV / Revenue | - | - | 1.93 x | 1.8 x | 1.55 x | 1.41 x |
| EV / EBITDA | - | - | 11.6 x | 9.67 x | 8.68 x | 7.87 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | 1.84 x | 1.86 x | 1.73 x | 1.44 x |
| Nbr of stocks (in thousands) | 2,570,037 | 2,570,037 | 2,570,037 | 2,544,332 | - | - |
| Reference price 2 | 6.150 | 4.730 | 5.050 | 5.480 | 5.480 | 5.480 |
| Announcement Date | 20-04-28 | 23-04-11 | 24-04-19 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 6,733 | 7,756 | 9,015 | 9,918 |
| EBITDA 1 | - | - | 1,116 | 1,443 | 1,606 | 1,772 |
| EBIT 1 | - | - | 788.3 | 1,058 | 1,307 | 1,447 |
| Operating Margin | - | - | 11.71% | 13.65% | 14.5% | 14.59% |
| Earnings before Tax (EBT) 1 | - | - | 767.7 | 1,044 | 1,290 | 1,432 |
| Net income 1 | -345.6 | 358.1 | 591.6 | 782.4 | 927.4 | 1,062 |
| Net margin | - | - | 8.79% | 10.09% | 10.29% | 10.71% |
| EPS 2 | -0.1300 | 0.1400 | 0.2300 | 0.3067 | 0.3633 | 0.4100 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | 0.2000 | 0.1400 | 0.1550 | - |
| Announcement Date | 20-04-28 | 23-04-11 | 24-04-19 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 1,549 | 1,824 | 1,794 | 1,829 | 1,965 |
| EBITDA | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - |
| Net income | 107.1 | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| EPS 2 | 0.0420 | -0.0100 | 0.0840 | 0.0700 | 0.0600 | 0.0300 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 23-10-27 | 24-04-19 | 24-04-26 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 8.45% | 10.1% | 11.6% | 10.9% |
| ROA (Net income/ Total Assets) | - | - | - | 6.6% | 7.3% | - |
| Assets 1 | - | - | - | 11,855 | 12,705 | - |
| Book Value Per Share 2 | - | - | 2.740 | 2.940 | 3.180 | 3.810 |
| Cash Flow per Share 2 | - | - | 0.3500 | 0.2500 | 0.4400 | 0.5400 |
| Capex 1 | - | - | 113 | 676 | 676 | - |
| Capex / Sales | - | - | 1.68% | 8.72% | 7.5% | - |
| Announcement Date | 20-04-28 | 23-04-11 | 24-04-19 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.48
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.51% | 1.93B | |
| +21.21% | 44.4B | |
| +24.60% | 23.03B | |
| +17.52% | 15.14B | |
| +12.90% | 13.12B | |
| +44.59% | 11.85B | |
| -8.33% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.22% | 5.52B |
- Stock Market
- Equities
- 600572 Stock
- Financials Zhejiang CONBA Pharmaceutical Co.,Ltd.